Abstract
As the coronavirus disease 2019 (COVID-19) pandemic evolves, new methods that enable real-world studies can provide public health information regarding long-term immunity following vaccination and booster campaigns. We conducted an observational trial to assess antibody levels against SARs-CoV-2 following COVID-19 vaccine boosters in adults in the United States during the omicron wave. This study utilized mobile health technology to recruit and enroll participants in combination with at-home blood collection self-conducted by participants and self-administration of surveys. The results show that when compared with the Pfizer-only primary/booster COVID-19 vaccine, the Moderna-only primary/booster vaccine substantially boosts and maintains high antibody titers over time against the ancestral strain and variants, including BA.1; the geometric mean ratios were generally statistically significantly greater when comparing the Moderna-only to the Pfizer-only vaccine/booster series over much of the study period. These observations suggest that priming/boosting with the Moderna vaccine may be highly protective against COVID-19; such data are vital to inform future recommendations for COVID-19 boosters and to assess the emergence of variants.
Competing Interest Statement
TD, NS, PB, FC, and BF are employees of Moderna, Inc., and hold stock/stock options in the company.
Clinical Trial
NCT05367908
Funding Statement
This study was funded by Moderna, Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Advarra Institutional Review Board (Columbia, Maryland, United States) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.